ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

EDEN Eden Research Plc

4.25
-0.10 (-2.30%)
25 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eden Research Plc LSE:EDEN London Ordinary Share GB0001646941 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.10 -2.30% 4.25 4.00 4.50 4.35 4.25 4.35 372,801 16:24:58
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Biological Pds,ex Diagnstics 1.83M -2.24M -0.0042 -10.12 22.67M
Eden Research Plc is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker EDEN. The last closing price for Eden Research was 4.35p. Over the last year, Eden Research shares have traded in a share price range of 3.20p to 12.00p.

Eden Research currently has 533,352,523 shares in issue. The market capitalisation of Eden Research is £22.67 million. Eden Research has a price to earnings ratio (PE ratio) of -10.12.

Eden Research Share Discussion Threads

Showing 11101 to 11114 of 17875 messages
Chat Pages: Latest  451  450  449  448  447  446  445  444  443  442  441  440  Older
DateSubjectAuthorDiscuss
15/10/2021
09:13
spadeychops 15 Oct '21 - 08:23 - 10769
> Yawn… bored!

ROFL! Sold up and ran, I see.

Ungrateful cur, why didn't you thank us?

neutralpov
15/10/2021
08:58
Continues to drop today. Just look at the trades...

As the penny gradually drops with our thicker brethren, so does the share price

neutralpov
14/10/2021
22:46
Is there really any difference in the WORDSOUP and CLAIMSTEW BS-Borscht from this mongrel dog of an AIM "share" between the blabbering from 2005, 2010, 2015 and now?

Doesn't seem like there's much of a change to me. Some different names.

But never any dosh.

Phases to come:
Dilution
Extermination - 0p in the £.

neutralpov
14/10/2021
16:51
Investing: Eden is very good at fine words, but less so at delivering sales. Perhaps to repeat myself, we have had 'significant' agreements in the past, none of which have generated sales. A few examples from Eden's annual reports and correspondence below. Is anyone surprised that markets no longer take Eden seriously.

October 2004 Eden announced that heads of agreement have been agreed with Thallo Eco Products Corporation to distribute the nematode treatment product extensively in the US with minimum royalties of US$15m over 10 years. Outcome: No payments forthcoming.

Eden announced that significant sales would deliver in 2005/06. Outcome: Turnover 2005 zero; 2006 102,559!

Jan 2006 Eden announced that the first product to be marketed under the Redestos agreement will be Eden’s encapsulated fungicidal product for treating botrytis, with anticipated revenues starting in 2007. Outcome: no marketing, Eden mired in EU approval process and regulation.

May 2006: personal letter: 'obtaining approval for use of 3AEY in this major market (USA) within two years maximum". Outcome: 2021 - still no US approval - unless I have missed something.

May 2006: (same letter): ' We do expect the product to soon be available in most major wine growing regions. Outcome: 2021 - sales minimal.

August 2007: 'concluded a major manufacturing and distribution agreement for Western Europe and the USA with Cheminova....this compliments the comapny's existing partnerships with Redestos SA in Greece and the Balkans, Zagro PTE in SE Asic and Xeda Intl in the post harvest sector. Cheminova is likely to start selling in Italy and Spain, then moving into France and Germany. Initial sales are likely to be small in 2008, with a full sales programme in 2009. Outome: non delivery. Sales still non-existent in 2012/2013 - £44k & £80k respectively.

erinvale1
14/10/2021
16:50
Investingisatrickygame 14 Oct '21 - 15:45 - 10763

> Annual Report 2020 From the Chairman's Statement
> "We have been delighted ... We have high hopes"

Their delight. Their high hopes.

The idiot punters' dosh, though.

ROTFL!!

neutralpov
14/10/2021
16:24
spadeychops 14 Oct '21 - 12:59 - 10761
> I clearly do know more than you, as I know for FACT, <—— look the word up, investing[isatrickygame] is not female

So stooopid and easy to trap.

Thanks for admitting you are one and the same person or on the same ramping team.

Any railway tracks near where you hang out?

neutralpov
14/10/2021
15:45
Annual Report 2020

From the Chairman's Statement

"We have been delighted to sign our first commercial agreement for seed treatment applications, which grants exclusive distribution rights of our proprietary product incorporating our Sustaine technology to Corteva Sciences, the fourth largest agricultural company in the world. We have high hopes for the commercial potential for this product area"

"The recently announced agreement with Corteva is, of course, significant to Eden"

"Eden is well positioned to capitalise on this trend (Growing food to feed larger populations more sustainably) as its products and technologies align closely with global demand for plastic-free and sustainable crops"

investingisatrickygame
14/10/2021
13:11
If you grant an entity distribution rights, such as Corteva, you cannot sell into that market. You are reliant on their goodwill to treat you fairly.Terravision v Google. Corporate US giants do not play a straight bat.Yes I take all of my investment advice from Netflix ?
ravenna23
14/10/2021
12:23
Farmers are a notoriously thrifty bunch. The marketing strategy here is all wrong, by relying on distributors for sales. Get the product into a couple of agri majors for trial. Once they prove it is cost effective everyone will want the product. Corteva are waiting to pick up the IP on the cheap. Successful entrepreneurs always put sales first. Eden appears to believe in the philosophy, build it and they will come.
ravenna23
14/10/2021
11:16
Yes unfortunately some investors are unable to comprehend the fact that good scientists do not always make excellent company managers. Denial of FRC concerns is another catalyst. Three words Sales, Sales, Sales. No sign of this therefore gurgler bound.
ravenna23
14/10/2021
10:43
Note to ravenna - A textbook case here of the support dropping away. Now just an intelligence test as to who jumps ship. Had they sold six months ago, and bought back six months from now, they could have about 7 times as many shares....

Steenkin' muppets. Gorra lurv 'em, my food supply.

neutralpov
13/10/2021
09:12
Competent, honest management
ravenna23
13/10/2021
09:08
I can see nothing which might transform Eden's share price and outlook, beyond a short-term spike if US approval is granted. The company now has distribution agreements with multiple A1 companies covering several products and countries, yet sales remain minimal. There appears no interest in buying out, even at this low level, despite the undoubted quality of Eden's IP. Can anyone suggest what might make a real difference?
erinvale1
13/10/2021
08:57
Support gone. Eden is headed down the gurgler. Next stop 5/6p. Cash runway 18 months before next capital raising. 3p? Sell now and next year your cash will buy you double the number of shares. Lost cause, IP is worthless without competent management. Financial results prove my point.
ravenna23
Chat Pages: Latest  451  450  449  448  447  446  445  444  443  442  441  440  Older

Your Recent History

Delayed Upgrade Clock